TC
RPRX

TFS Capital’s Repros Therapeutics Inc. RPRX Stock Holding History

TFS Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-16,261
Closed -$34K – 1042
2016
Q3 		$34K Buy
+16,261
New +$32.2K 0.01% 718
2015
Q4 		– Sell
-10,733
Closed -$80K – 1125
2015
Q3 		$80K Buy
+10,733
New +$82.1K 0.01% 818

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

TFS Capital's RPRX Position: Q4 2016 in Review

TFS Capital sold out of Repros Therapeutics Inc. (RPRX) in Q4 2016, closing a stake of 16,261 shares — an estimated $34K sold.

TFS Capital first reported a position in RPRX in Q3 2015 and held it in 2 quarters. The position peaked at $80K in Q3 2015. 43 funds tracked by Wall St. Rank hold RPRX as of Q4 2016.

  • TFS Capital reported no remaining Repros Therapeutics Inc. position as of Q4 2016 after selling out during the quarter.
  • TFS Capital sold 16,261 Repros Therapeutics Inc. shares in Q4 2016, an estimated $34K.
  • TFS Capital first reported a position in Repros Therapeutics Inc. in Q3 2015 and held it in 2 quarters.
  • TFS Capital's Repros Therapeutics Inc. position peaked at $80K in Q3 2015.
  • 43 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2016.

Based on TFS Capital's 13F filing for Q4 2016, filed 20 Jan 2017.